Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

Bullfinch Aug. 14 at 2:53 PM

$VTVT Nice move up! The news is settling in and the ride can slowly start

0 · Reply

Jacks10 Aug. 14 at 2:27 PM

$VTVT let's hit $20's

0 · Reply

Zonata Aug. 14 at 1:55 AM

$VTVT Am I correct is assuming they have to raise to finish their Phase III? I expected Phase 3 topline to be H1 2026.

1 · Reply

JarvisFlow Aug. 13 at 12:00 PM

HC Wainwright & Co. updates rating for vTv Therapeutics ( $VTVT ) to Buy, target set at 36.

0 · Reply

Bullfinch Aug. 13 at 7:06 AM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-reports-second-quarter-2025-financial-results

0 · Reply

Enzo10 Aug. 12 at 5:50 PM

$VTVT are we all dead?

1 · Reply

GDS_investing Aug. 11 at 3:29 PM

$VTVT and more great news out: " vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin" https://finance.yahoo.com/news/vtv-therapeutics-announces-uspto-allowance-120000042.html very low float only 640k volume is the key for fast runup ! in a support buy area LONG AND STRONG $VTVT watch $EQ $BJDX $TLS

1 · Reply

GDS_investing Aug. 7 at 2:22 PM

$VTVT good NEWS out "vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes" https://finance.yahoo.com/news/vtv-therapeutics-announces-first-study-120000264.html very low float only 640k volume is the key for fast runup long and strong $VTVT

1 · Reply

Bullfinch Aug. 7 at 12:09 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-first-study-participant-randomized

0 · Reply

Samiam69 Jul. 31 at 3:16 PM

$VTVT halted if it is bad news like the last we are fucked

2 · Reply

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 8 days ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 12 days ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 3 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 3 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 3 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 5 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 1:59 PM EDT - 5 months ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 8:30 AM EDT - 5 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 9 months ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 9 months ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 1 year ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 1 year ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Mar 6, 2023, 5:56 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 8:02 AM EST - 2 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Feb 27, 2023, 8:02 AM EST - 2 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 1, 2023, 5:00 PM EST - 2 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Jan 9, 2023, 8:00 AM EST - 2 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Dec 13, 2022, 8:15 AM EST - 2 years ago

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Nov 10, 2022, 5:25 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Aug 15, 2022, 6:43 PM EDT - 3 years ago

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Jul 27, 2022, 7:00 AM EDT - 3 years ago

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

Jul 25, 2022, 7:00 AM EDT - 3 years ago

vTv Therapeutics Announces Investment by CinRx Pharma

Jun 4, 2022, 11:00 AM EDT - 3 years ago

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Jun 1, 2022, 6:54 AM EDT - 3 years ago

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

May 12, 2022, 7:45 AM EDT - 3 years ago

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

Bullfinch Aug. 14 at 2:53 PM

$VTVT Nice move up! The news is settling in and the ride can slowly start

0 · Reply

Jacks10 Aug. 14 at 2:27 PM

$VTVT let's hit $20's

0 · Reply

Zonata Aug. 14 at 1:55 AM

$VTVT Am I correct is assuming they have to raise to finish their Phase III? I expected Phase 3 topline to be H1 2026.

1 · Reply

JarvisFlow Aug. 13 at 12:00 PM

HC Wainwright & Co. updates rating for vTv Therapeutics ( $VTVT ) to Buy, target set at 36.

0 · Reply

Bullfinch Aug. 13 at 7:06 AM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-reports-second-quarter-2025-financial-results

0 · Reply

Enzo10 Aug. 12 at 5:50 PM

$VTVT are we all dead?

1 · Reply

GDS_investing Aug. 11 at 3:29 PM

1 · Reply

GDS_investing Aug. 7 at 2:22 PM

1 · Reply

Bullfinch Aug. 7 at 12:09 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-first-study-participant-randomized

0 · Reply

Samiam69 Jul. 31 at 3:16 PM

$VTVT halted if it is bad news like the last we are fucked

2 · Reply

km1663 Jul. 31 at 2:55 PM

$VTVT Would be nice if this could have SNGX moment.

0 · Reply

dcajic2 Jul. 30 at 3:37 PM

$VTVT How will this company survive?? They do not inform of any progress. They didn’t inform the many months they had a clinical hold and clinical hold has been over 4 months and still no word. Company continues to pay executives month after month for doing exactly what

0 · Reply

ConstanceAtkeson887 Jul. 23 at 4:35 PM

$VTVT is aiming at metabolic therapies, but RMTG is treating patients today. Their Puerto Rico launch adds geographic and regulatory leverage.

0 · Reply

km1663 Jul. 16 at 8:13 PM

$VTVT Topline data from the CATT1 Phase 3 trial for cadisegliatin (TTP3999) is anticipated in the second half of 2026. Does anyone know if we could have any other data/trial releases b4 then that could juice this stock?

0 · Reply

Icabod63 Jul. 16 at 1:16 PM

Wishful thinking and hoping today for some positivity! $VSTM gets and holds $5.00 plus, $DARE gets to $3.00 plus and holds, and $VTVT gets to $17.00 plus and holds. Baby steps to hopefully keep the shorts away?

0 · Reply

dcajic2 Jul. 14 at 12:02 PM

$VTVT company has no accountability. Has many employees doing exactly what? They go for many many months and say nothing. How can you trust people that take rather big salaries and no updates. What exactly are they doing? Have they even enrolled anybody

0 · Reply

dcajic2 Jul. 14 at 12:00 PM

$VTVT The float is more than 2 million do The math

0 · Reply

GDS_investing Jul. 13 at 6:20 PM

$INKT i bet $VTVT is the next float only 640k long $INKT and $VTVT

0 · Reply

GDS_investing Jul. 11 at 4:35 PM

$INKT great call here glat my followers holding $VTVT $RFL $SSKN for next runup long

0 · Reply

dcajic2 Jul. 11 at 4:31 PM

$VTVT how can anyone trust a company that does not update people on the progression of their company. For month they had a clinical hold and said nothing. Then they finally had the clinical hold lifted after close to 5 months and now it’s going into the fourth month of clinical hold being lifted and they still don’t talk

0 · Reply

Invest2live Jul. 8 at 7:00 PM

$VTVT congrats; check out $LCTX

0 · Reply

Jacks10 Jul. 8 at 6:49 PM

$VTVT I want to see $30's soon!

0 · Reply

Market Cap	49.33M
Revenue (ttm)	1.02M
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,809.80%
Debt to Equity Ratio	0.00

Volume	2,700
Avg Vol	4,920
Day's Range	N/A - N/A
Shares Out	3.20M
Stochastic %K	76%
Beta	0.57
Analysts	Sell
Price Target	$35.50